


**PANCREATIC
CANCER
ACTION
NETWORK**

**Taking bold action to improve the lives of
pancreatic cancer patients**

Improve Patient Outcomes



5-year relative survival rate

As reported on the indicated year by

*American Cancer Society, Cancer Facts and Figures
1999-2022, SEER-9 and SEER-18 Databases*

Our approach:

Fig
pa
ca
ev

Research



PanCAN Patient Services




Government Advocacy




Community



Including \$25M in 2022!



**GRANTS
PROGRAM**



**KNOW YOUR
TUMOR[®]**



**PATIENT
REGISTRY**



**PRECISION
PROMISESM**



**EARLY
DETECTION
INITIATIVE**



**SPARK
HEALTH DATA
PLATFORM**


PRECISION PROMISE:

ADAPTIVE – *LEARN AS YOU GO*

PLATFORM – *MULTIPLE THERAPIES TESTED SIMULTANEOUSLY*

TRIAL – *PanCAN IS THE SPONSOR*

Open at >20 sites



**PANCREATIC
CANCER
ACTION
NETWORK**

THE GRANTS PROGRAM

Unmet need: How can we incentivize Pharma/Biotech to invest in a pancreatic cancer indication for their new therapies and build the Precision Promise pipeline?


Pancreatic Cancer often not a priority by Pharma/Biotech due to high risk and market size

Early-Stage development decisions continue to favor cancers outside of pancreatic cancer


Need to accelerate early-stage development by directly funding Pharma/Biotech

- Up to \$5M in support to offset cost of testing approach in an early-stage (Phase I/II) PDAC clinical trial
- Company holds the IND and retains all IP rights
- Focus: to accelerate the development of therapeutic strategies that address vulnerabilities found in a significant portion (>20%) of pancreatic ductal adenocarcinoma (PDAC) cases
 - 2022 major priority: therapies that target KRAS G12D and/or G12V mutations, combinations of inhibitors of downstream pathways of KRAS shown to display synthetic lethality, or metabolic vulnerabilities identified as being major contributors to PDAC growth and survival
 - 2023 major priority: strategies that reverse the immunosuppressive tumor microenvironment and/or help achieve a robust immune response
 - Other approaches considered and evaluated based on quality and abundance of supporting evidence

Criteria




Key Decision Makers



WORKING GROUP

- Unlikely the trial will be the last one ever
- How can we make it better in the future?
 - What worked?
 - What didn't work?
 - Does it work best on a subset of patients?
 - What other combinations would be better?
- 5 investigators chosen for their expertise
 - Submitted proposals
 - Proposals modified and approved for funding through our flexible Catalyst Award program
 - \$1.5M total
- PanCAN, TAA recipient, and Precision Promise academic investigator lead Working Group
 - Monthly 90-minute calls for progress, collaboration



Award to Pharma/Biotech company

Peer Review Process – inclusion of PanCAN Board of Directors with expertise in drug development and venture capital, as well as partnership with Skipper BioMed to develop business scoring tool and conduct business due diligence review

Correlative/Ancillary studies to address pathway assumptions in main clinical trial

Outcomes expected to advance new treatments for pancreatic cancer in the near term

**Short Term Outcome:**

Readiness to move on to later stage development in Precision PromiseSM clinical trial

**Long Term Outcome:**

Successful transition to Phase III of Precision PromiseSM and approval by the FDA

- Robust appetite for award mechanism based on number of companies expressing interest
- Good to build in LOI process to prepare for peer review
- There is a need to incorporate expertise that understands the business of Pharma/Biotech entities
- Can influence Pharma/Biotech via such a funding mechanism by focusing them on certain types of research (e.g., immunotherapy studies)

Questions?